Anti-Human HLA-DP (MHC Class II) Monomorphic - Purified in vivo GOLD™ Functional Grade
Cat# H260-25
Size : 25mg
Brand : Leinco Technologies
AntiHuman HLADP (MHC Class II) Monomorphic – Purified in vivo GOLD™ Functional Grade
AntiHuman HLADP (MHC Class II) Monomorphic – Purified in vivo GOLD™ Functional Grade
Product No.: H260
Clone B7/21 Target HLADP Monomorphic Formats AvailableView All Product Type Monoclonal Antibody Alternate Names HLADP Monomorphic, HLADP, HLADPαβ, DPA and DPB, DPα and DPβ, DPαβ Isotype Mouse IgG3 Applications FC , ICC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Mouse IgG3 Recommended Dilution Buffer Immunogen Unknown Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 28°C RRIDAB_2737518 Applications and Recommended Usage? Quality Tested by Leinco FC Additional Applications Reported In Literature ? ICC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone B7/21 recognizes a monomorphic epitope on human HLADP1, DP2, DP3, DP4, and DP5. It does not crossreact with HLADR or HLADQ. Background HLADP antibody, clone B7/21, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen DP isotype (HLADP). MHC class II is constitutively expressed on human professional antigenpresenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation1. HLADP consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain2 encoded by the HLADPA1 and HLADPB1 genes, respectively, located in the HLA complex of chromosome 6. The Nterminal α1 and β1 domains form the antigenbinding groove, which binds 1325 aa peptides derived from exogenous antigens3. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptideMHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling4. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation5 and can transduce signals into T cells, enhancing T cell proliferation and activity6. High HLADP expression is associated with an increased risk of graftversushost disease7. Specific alleles of HLADP are associated with autoimmune diseases, including rheumatoid arthritis8. Antigen Distribution HLADP is expressed on antigenpresenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells. PubMed Research Area Immunology . Innate Immunity References & Citations1. Holling TM, et al. (2004) Hum Immunol. 65(4):28290. 2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):1061825. 3. Wieczorek M, et al. (2017) Front Immunol. 8:292. 4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):1691616921. 5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):715. 6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):25160. 7. Petersdorf EW, et al. (2015) N Engl J Med. 373(7):599609. 8. Raychaudhuri S, et al. (2012) Nat Genet. 44(3):2916. |